- Home
- AZTA vs TNGX Comparison
AZTA vs TNGX Comparison
Compare AZTA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZTA | TNGX |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | AZTA | TNGX |
|---|---|---|
| Price | $35.37 | $9.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $43.60 | $12.50 |
| AVG Volume (30 Days) | 652.7K | ★ 2.9M |
| Earning Date | 11-21-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $593,821,000.00 | $66,501,000.00 |
| Revenue This Year | $6.13 | $53.01 |
| Revenue Next Year | $5.02 | N/A |
| P/E Ratio | $66.13 | ★ N/A |
| Revenue Growth | 3.55 | ★ 53.29 |
| 52 Week Low | $23.91 | $1.03 |
| 52 Week High | $55.64 | $11.20 |
Technical Indicators
Market Signals| Indicator | AZTA | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 55.06 |
| Support Level | $34.49 | $9.46 |
| Resistance Level | $38.20 | $10.22 |
| Average True Range (ATR) | 1.57 | 0.69 |
| MACD | 0.13 | -0.03 |
| Stochastic Oscillator | 66.38 | 54.27 |
Price Performance
Historical ComparisonAbout AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.